Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:08 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
The Norwegian Tenecteplase Stroke Trial 2
NCT03854500 · Haukeland University Hospital · PHASE3 · terminated · last registry update 2025-03-03 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Per protocol safety analysis 200 patients showed a significant difference in bleeding rates between the two drug groups.” | – | Registry record, Haukeland University Hospital |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PLAT within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-01-23Phase 3 first posted: Boehringer Ingelheim, Tenecteplase + Standard of care treatment (NCT07361302)
- 2026-01-16Phase 3 first posted: Xinqiao Hospital of Chongqing, Eptifibatide (Integrilin) + Standard Medical Therapy (NCT07347626)
- 2025-12-24Phase 3 first posted: Xiang Luo, Standard medical treatment (NCT07302854)
- 2025-11-28Phase 3 first posted: Xuanwu Hospital, Beijing, Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg) (NCT07253181)
- 2025-10-01Phase 3 first posted: CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd., rhTNK-tPA + Placebo (NCT07201688)
- 2025-09-11Phase 3 first posted: The First Affiliated Hospital of University of Science and Technology of China, TNK + Standard medical treatment (NCT07168278)
- 2025-09-09Phase 3 first posted: University of Illinois Chicago, Deferoxamine (NCT07162363)
- 2025-08-28Phase 3 first posted: AO GENERIUM, Revelise (GENERIUM, Russia) + Actilyse® (Boehringer Ingelheim Pharma GmbH and Co.KG, Germany) (NCT07146360)
- 2025-08-11Results posted on the registry: University College, London, Nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 1 + Nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 2 IMV (NCT04356833)
- 2025-07-30Phase 3 first posted: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg) + Placebo (NCT07092709)
- 2025-07-25Also stopped (terminated): University Hospital, Caen, N-Acetyl cysteine (NCT04920448)
- 2025-07-25Also stopped (terminated): University Hospital, Caen, EVD + IVF with Alteplase (NCT03187405)
- 2025-07-18Phase 3 first posted: Second Affiliated Hospital, Zhejiang University, School of Medicine, Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg) (NCT07073469)
- 2025-07-02Phase 3 first posted: Beijing Tiantan Hospital, Tenecteplase (0.25mg/kg) + Standard medical treatment (NCT07047014)
- 2025-07-02Also stopped (terminated): General Hospital of Shenyang Military Region, Tenecteplase (NCT05657457)
- 2025-05-01Phase 3 first posted: Beijing Tiantan Hospital, Tenecteplase (0.25mg/kg) + Standard medical treatment (NCT06954155)
- 2025-04-29Phase 3 first posted: ProMedica Health System, tenecteplase (NCT06949228)
- 2025-04-02Results posted on the registry: Supergene, LLC, Recombinant staphylokinase + Alteplase (NCT03151993)
- 2025-04-02Results posted on the registry: Supergene, LLC, Recombinant nonimmunogenic staphylokinase + Alteplase (NCT04688320)
- 2025-03-20Results posted on the registry: Supergene, LLC, Recombinant staphylokinase + Tenecteplase (NCT02301910)
- 2025-03-14Phase 3 first posted: Guri Hagberg, thrombolysis therapy (NCT06878066)
- 2025-03-11Phase 3 first posted: Beijing Tiantan Hospital, Standard medical treatment (NCT06868511)
- 2025-02-24Phase 3 first posted: Second Affiliated Hospital, Zhejiang University, School of Medicine, Intravenous thrombolysis (NCT06841965)
- 2025-02-24Phase 3 first posted: Second Affiliated Hospital, Zhejiang University, School of Medicine, Intravenous Thrombolysis (NCT06841978)
- 2025-02-21Also stopped (withdrawn): Prisma Health-Midlands, early tPA and DNase (NCT03167281)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision